Replimune Group (REPL) Competitors $11.23 +0.28 (+2.56%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends REPL vs. VIR, ALVR, ATRA, BLUE, BEAM, MRUS, XENE, HCM, VERA, and MORShould you be buying Replimune Group stock or one of its competitors? The main competitors of Replimune Group include Vir Biotechnology (VIR), AlloVir (ALVR), Atara Biotherapeutics (ATRA), bluebird bio (BLUE), Beam Therapeutics (BEAM), Merus (MRUS), Xenon Pharmaceuticals (XENE), HUTCHMED (HCM), Vera Therapeutics (VERA), and MorphoSys (MOR). These companies are all part of the "medical" sector. Replimune Group vs. Vir Biotechnology AlloVir Atara Biotherapeutics bluebird bio Beam Therapeutics Merus Xenon Pharmaceuticals HUTCHMED Vera Therapeutics MorphoSys Vir Biotechnology (NASDAQ:VIR) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, community ranking, valuation, risk and analyst recommendations. Which has preferable valuation and earnings, VIR or REPL? Replimune Group has lower revenue, but higher earnings than Vir Biotechnology. Replimune Group is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVir Biotechnology$86.18M10.77-$615.06M-$3.92-1.72Replimune GroupN/AN/A-$215.79M-$3.05-3.68 Does the media favor VIR or REPL? In the previous week, Replimune Group had 2 more articles in the media than Vir Biotechnology. MarketBeat recorded 19 mentions for Replimune Group and 17 mentions for Vir Biotechnology. Replimune Group's average media sentiment score of 0.69 beat Vir Biotechnology's score of 0.52 indicating that Replimune Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vir Biotechnology 4 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Replimune Group 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is VIR or REPL more profitable? Replimune Group has a net margin of 0.00% compared to Vir Biotechnology's net margin of -678.40%. Vir Biotechnology's return on equity of -36.71% beat Replimune Group's return on equity.Company Net Margins Return on Equity Return on Assets Vir Biotechnology-678.40% -36.71% -31.00% Replimune Group N/A -53.12%-41.49% Does the MarketBeat Community believe in VIR or REPL? Replimune Group received 113 more outperform votes than Vir Biotechnology when rated by MarketBeat users. Likewise, 63.04% of users gave Replimune Group an outperform vote while only 53.26% of users gave Vir Biotechnology an outperform vote. CompanyUnderperformOutperformVir BiotechnologyOutperform Votes4953.26% Underperform Votes4346.74% Replimune GroupOutperform Votes16263.04% Underperform Votes9536.96% Do analysts recommend VIR or REPL? Vir Biotechnology currently has a consensus price target of $36.40, suggesting a potential upside of 440.06%. Replimune Group has a consensus price target of $16.80, suggesting a potential upside of 49.60%. Given Vir Biotechnology's higher probable upside, research analysts plainly believe Vir Biotechnology is more favorable than Replimune Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vir Biotechnology 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60Replimune Group 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Do institutionals and insiders believe in VIR or REPL? 65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 92.5% of Replimune Group shares are held by institutional investors. 15.6% of Vir Biotechnology shares are held by company insiders. Comparatively, 8.8% of Replimune Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more risk & volatility, VIR or REPL? Vir Biotechnology has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500. Comparatively, Replimune Group has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. SummaryReplimune Group beats Vir Biotechnology on 12 of the 18 factors compared between the two stocks. Ad DarwinNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Get Replimune Group News Delivered to You Automatically Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart REPL vs. The Competition Export to ExcelMetricReplimune GroupBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$749.17M$2.94B$5.05B$8.87BDividend YieldN/A1.89%4.97%4.06%P/E Ratio-3.6821.3797.3414.18Price / SalesN/A382.101,218.4289.42Price / CashN/A160.1133.5132.79Price / Book2.014.195.805.12Net Income-$215.79M-$41.63M$119.07M$225.99M7 Day Performance-1.49%-4.73%-1.83%-1.32%1 Month Performance-1.06%-6.53%-3.64%0.60%1 Year Performance7.67%25.63%31.62%26.23% Replimune Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)REPLReplimune Group4.2366 of 5 stars$11.23+2.6%$16.80+49.6%+10.3%$749.17MN/A-3.68210VIRVir Biotechnology3.019 of 5 stars$6.74-2.7%$36.40+440.1%-31.2%$954.40M$86.18M0.00587Analyst ForecastALVRAlloVir2.6268 of 5 stars$0.57+1.8%N/A-65.2%$65.87MN/A-0.65110Positive NewsATRAAtara Biotherapeutics3.8122 of 5 stars$10.68-2.8%$16.67+56.1%-23.4%$61.52M$8.57M-0.41165BLUEbluebird bio2.8596 of 5 stars$0.30flat$3.03+898.3%-92.1%$58.92M$29.50M-0.17323Analyst ForecastBEAMBeam Therapeutics2.9185 of 5 stars$24.49-3.2%$44.91+83.4%-20.4%$2.03B$377.71M-13.91461MRUSMerus1.9713 of 5 stars$42.93-1.3%$86.70+102.0%+76.7%$2.98B$43.95M0.0037Analyst ForecastXENEXenon Pharmaceuticals3.4913 of 5 stars$39.34+1.3%$57.45+46.0%+35.2%$2.96B$9.43M0.00251Analyst RevisionHCMHUTCHMED1.1549 of 5 stars$17.96+7.2%$20.55+14.4%-3.1%$2.92B$838M0.001,988Analyst DowngradeNews CoverageGap UpVERAVera Therapeutics3.3108 of 5 stars$45.75-0.3%$57.88+26.5%+238.9%$2.91BN/A0.0040MORMorphoSys0.1673 of 5 stars$18.96flat$11.78-37.9%N/A$2.86B$238.28M-5.45730 Related Companies and Tools Related Companies Vir Biotechnology Alternatives AlloVir Alternatives Atara Biotherapeutics Alternatives bluebird bio Alternatives Beam Therapeutics Alternatives Merus Alternatives Xenon Pharmaceuticals Alternatives HUTCHMED Alternatives Vera Therapeutics Alternatives MorphoSys Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:REPL) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Replimune Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free REPL Stock Alerts